Pediatric Pulmonology · 2021 · 10 citations · 27 references
MedicineClinical SciencesInternal MedicineMedical MicrobiologyPulmonary Function TestingPulmonologyCystic FibrosisPulmonary AssessmentPulmonary Function AssessmentPulmonary InfectionsRespiratory DiseaseRespiratory InfectionsChronic Pseudomonas Aeruginosa InfectionClearance In The LungCystic Fibrosis Lung DiseaseDuration Of Antibiotic TreatmentForced Expiratory Volume AssessmentForced Expiratory Volume DeclinePseudomonas SpeciesPulmonary Exacerbations
Abstract Background Normal values (>80%) of Forced Expiratory Volume in one second (FEV 1 ) in patients with cystic fibrosis (CF) may lead to the interpretation that there is no lung disease. This study is a comprehensive analysis of lung involvement in CF patients having normal FEV 1 . Methods Patients were recruited from two CF centers: Hadassah Medical Center, Jerusalem and Vall d' Hebron Hospital, Barcelona. Lung disease was assessed by lung clearance index (LCI), chest CT‐Brody score, respiratory cultures, number of pulmonary exacerbations (PEx), and days of antibiotic treatment in the year before the assessment. Results Of the 247 patients, 89 (36%) had FEV 1 ≥80% and were included in the study (mean age, 17.6; range, 4.25–49 years). Chronic Pseudomonas aeruginosa infection was found in 21%, and 31% had at least one major PEx in the year before the study. Abnormally elevated LCI was found in 86% of patients, ranging between 7.52 and 18.97, and total Brody score (TBS) was abnormal in 92% (range, 5.0–96.5). Patients with chronic P. aeruginosa had significantly higher LCI ( p = .01) and TBS ( p = .02) which were associated with more major PEx ( p < .01 and p = .01, respectively) and more days of intravenous (IV) antibiotic treatment in the preceding year ( p = .03 and p = .001, respectively). Conclusions Most CF patients with normal FEV 1 have already physiological and structural lung abnormalities which were associated with more PEx and IV antibiotic treatment. Further studies are needed to determine if better adherence to the currently used therapies and the new cystic fibrosis transmembrane modulators will prevent the progression of lung disease.
27
Martin R. Miller, J. Hankinson, Vito Brusasco et al. · European Respiratory Journal · 2005 · 15.7K citations · Full text
Prediction of Mortality in Patients with Cystic Fibrosis
Eitan Kerem, Joseph Reisman, Mary Corey et al. · New England Journal of Medicine · 1992 · 987 citations